Our results specifically implicate tumor cell-produced MMP9 in invasion and metastatic progression in models of basal-like triple negative breast cancer, and suggest MMP9 as a potential therapeutic target to combat metastasis in this poor prognosis breast cancer subtype for which few current molecularly targeted therapies are effective. Here, MMP9 is linked to neoplasm.